Search clinical trials for: ALVAC-hB7.1

Total 72 results

National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

Recurrent Ovarian Epithelial Cancer

United States
National Institute of Allergy and Infectious Diseases...
National Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute... and other collaborators

Completed

Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers

HIV Infections

Uganda
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID)

Active, not recruiting

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E

HIV Infections

Thailand
University of Miami

Terminated

Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy

Lung Cancer

United States
U.S. Army Medical Research and Development Command
National Institutes of Health (NIH)

Unknown

Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144

HIV Infections

Thailand
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm

HIV Infections | HIV Seronegativity

United States
Walter Reed Army Institute of Research (WRAIR)

Unknown

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...
ANRS, Emerging Infectious Diseases

Completed

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers

HIV Infections | HIV Seronegativity

United States
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

HIV-1 Infection
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Ontario HIV Treatment Network; CIHR Canadian HIV Trials Network

Completed

Combination Vaccination Before HIV Treatment Interruption

HIV Infections

Canada
National Institute of Allergy and Infectious Diseases...

Completed

ALVAC-HIV vCP1452 Alone and Combined With MN rgp120

HIV Infections | HIV Seronegativity

Brazil, Peru, Haiti, Trinidad and Tobago
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR); Mahidol University; The Emmes... and other collaborators

Completed

HIV Vaccine Trial in Thai Adults

HIV Infection

Thailand
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

HIV Infections | HIV Seronegativity

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Puma Biotechnology, Inc.

Terminated

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Metastatic Cervical Cancer | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Spain, Israel, United States, Serbia, France, Ireland, Italy
Walter Reed Army Institute of Research (WRAIR)

Completed

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council; Sanofi... and other collaborators

Completed

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

HIV Infection

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Sanofi; GlaxoSmithKline; Bill and Melinda Gates Foundation

Completed

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702)

HIV Infections

South Africa
Centro de Educación Medica e Investigaciones Clínicas...
National Council of Scientific and Technical Research, Argentina; Laboratorio... and other collaborators

Completed

ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine (ARVAC-F2/3)

COVID-19 Vaccine

Argentina
National Cancer Institute (NCI)

Completed

PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer

Prostate Cancer | Prostate Neoplasm

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
MRC/UVRI and LSHTM Uganda Research Unit; Fogarty International Center of the... and other collaborators

Completed

Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda

HIV Infections

Uganda
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452

HIV Infections

United States
French National Agency for Research on AIDS and...
Aventis Pharmaceuticals

Terminated

HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

HIV Infection
Excelsior

Completed

A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

Trientine Treatment for Wilson's Disease

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Pasteur Merieux Connaught

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors

Cytomegalovirus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (HVTN 120)

HIV Infections

United States, Zimbabwe, Tanzania, Zambia
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Test the Safety of Three Experimental HIV Vaccines

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults (HVTN 097)

HIV Infection

South Africa
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute; New York University Cancer Institute

Completed

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

HIV Infections

United States, Puerto Rico
Karolinska Institutet
Region Stockholm

Recruiting

Optimization of Guidance in a Digital Tool for Problematic Alcohol Use

Drinking Excessive

Sweden
National Institute of Allergy and Infectious Diseases...
New York Presbyterian Hospital

Completed

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

HIV Infections

United States

Search clinical trials for: ALVAC-hB7.1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations